Will the FDA approve MAIA Biotechnology's THIO-101 for the treatment of advanced Non-Small Cell Lung Cancer by Jan 2030?
Santé et médecineOne-Off3a
Manifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleOui 84.3%
Prévisionnistes
3
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 1 heure
En retard26 oct. 23, 03:15 UTC2 janv. 30, 07:59 UTC
Tendances
Règles
1: The market resolves as "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for THIO-101 as a treatment for advanced Non-Small Cell Lung Cancer by the specified date.
- 2: The market resolves as "No" if the FDA explicitly rejects the application for THIO-101 for the mentioned indication by the specified date.
- 3: If neither approval nor rejection is announced by the FDA by the specified date, the market will resolve as "No."
- Context: https://www.businesswire.com/news/home/20231024406334/en/
- [link preview]
